Intellipharmaceutics
30 Worcester Road
Toronto
Ontario
M9W 5X2
Canada
Tel: 416-798-3001
Fax: 416-798-3007
Website: http://www.intellipharmaceutics.com/
163 articles about Intellipharmaceutics
-
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
3/13/2024
Intellipharmaceutics International Inc. announces its listing on NEX, a separate board of the TSX Venture Exchange.
-
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
2/26/2024
Intellipharmaceutics International Inc. announced that its annual audited financial statements for the fiscal year ended November 30, 2023, related management's discussion and analysis and accompanying Chief Executive Officer and Chief Financial Officer certificates and annual information form for the fiscal year ended November 30, 2023 due February 28, 2024 will not be filed by the Filing Deadline.
-
Intellipharmaceutics International Inc. Announces Stock Option Grant - February 08, 2024
2/8/2024
Intellipharmaceutics International Inc. announces that, the Company has issued 1,910,000 common share purchase options pursuant to the Company's stock option plan.
-
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
1/2/2024
Intellipharmaceutics International Inc. announces that, it has applied and received conditional approval to list the Company's common shares for trading on the TSX Venture Exchange as a Tier 2 Life Science Issuer.
-
Intellipharmaceutics Reports Director Election Results - September 14, 2023
9/14/2023
Intellipharmaceutics International Inc. reports, as required by TSX rules, that the five nominees, each of whom was an incumbent director of the Company, identified in the Management Information Circular dated August 1, 2023 were elected as directors of the Company at the annual meeting of shareholders of the Company.
-
Intellipharmaceutics Announces Second Quarter 2023 Results
7/14/2023
Intellipharmaceutics International Inc. today reported the results of operations for the three and six months ended May 31, 2023.
-
Intellipharmaceutics Announces Third Quarter 2022 Results
10/14/2022
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and nine months ended August 31, 2022.
-
Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
8/16/2022
Intellipharmaceutics International Inc announced that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc., by which the Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory of Health Canada.
-
Intellipharmaceutics Announces Second Quarter 2022 Results
7/21/2022
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and six months ended May 31, 2022.
-
Intellipharmaceutics Announces Delay in Filing Second Quarter Results Due July 15, 2022, The Financial Statements Will be Filed By July 21, 2022
7/15/2022
Intellipharmaceutics International Inc. announced today that its financial statements for the interim period ended May 31, 2022 and related management's discussion due July 15, 2022 (the "Filing Deadline") will not be filed by the Filing Deadline.
-
Intellipharmaceutics Reports Director Election Results - May 27, 2022
5/27/2022
Intellipharmaceutics International Inc. reports, as required by TSX rules, that the five nominees, each of whom was an incumbent director of the Company, identified in the Management Information Circular dated April 12, 2022 were elected as directors of the Company at the annual meeting of shareholders of the Company.
-
Intellipharmaceutics Announces First Quarter 2022 Results
4/14/2022
Intellipharmaceutics International Inc. and, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three months ended February 28, 2022.
-
Intellipharmaceutics Announces Fiscal Year 2021 Results
2/28/2022
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the year ended November 30, 2021.
-
Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead
1/13/2022
Intellipharmaceutics International Inc. and, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced with great sadness that Kenneth Keirstead, a member of the Company's Board of Directors, has passed away.
-
Intellipharmaceutics Comments on Recent Trading Activity
12/22/2021
Intellipharmaceutics International Inc. is issuing this press release in response to a request from the Investment Industry Regulatory Organization of Canada to comment on the recent trading activity of its stock.
-
Intellipharmaceutics Announces Third Quarter 2021 Results
10/15/2021
Intellipharmaceutics International Inc. and, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and nine months ended August 31, 2021.
-
Intellipharmaceutics Announces Second Quarter 2021 Results
7/15/2021
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and six months ended May 31, 2021.
-
Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement
4/22/2021
Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, is pleased to announce the completion of a non-brokered private placement of 9,414,560 common shares of the Company
-
Intellipharmaceutics Announces First Quarter 2021 Results
4/14/2021
Intellipharmaceutics International Inc. a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2021.
-
Intellipharmaceutics Announces Fiscal Year 2020 Results
3/1/2021
Intellipharmaceutics International Inc. and, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the year ended November 30, 2020.